IDEAYA Biosciences IDYA 深 沪
已收盘 05-08 16:00:00 美东时间
28.32
+0.080
+0.28%
华盛通- 最 高28.64
- 今 开28.20
- 成交量 54.58万股
- 最 低 28.01
- 昨 收 28.24
- 总市值 248.82万
- 52周最高 39.28
- 市盈率 静 --
- 换手率 0.62%
- 52周最低 17.17
- 委 比 -92.28%
- 总股本 8.79万
- 历史最高 47.735
- 量 比 0.62
- 振 幅 2.23%
- 历史最低 2.95
- 每 手 1
- 风险率 5.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Mizuho Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $50
Mizuho analyst Graig Suvannavejh maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $52 to $50.
05-07 20:32
一季报落幕：中国创新药进入商业化深水区
（来源：深蓝观） 吴妮 | 撰文 又一 | 编辑 随着今天百济神州一季报的发布，创新药企第一季度成绩单差不多落定。 财报季大家最关心的无非两件事...
05-06 20:32
财报速睇 | IDEAYA Biosciences 2026财年Q1营收0.07亿美元，去年同期无营收；归母净利润亏损0.99亿美元，同比亏损扩大36.5%
华盛资讯5月6日讯，IDEAYA Biosciences公布2026财年Q1业绩，公司Q1营收0.07亿美元，去年同期无营收，归母净利润亏损0.99亿美元，同比亏损扩大36.5%。
05-06 10:32
IDEAYA Biosciences Files Prospectus For Mixed Shelf Offering; Size Not Disclosed
-SEC Filing
05-06 05:40
Earnings Scheduled For May 5, 2026
Companies Reporting Before The Bell • Repligen (NASDAQ:RGEN) is projected to re...
05-05 19:12
IDEAYA Biosciences Q1 EPS $(1.11) Misses $(0.98) Estimate, Sales $6.560M Beat $5.008M Estimate
IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.98) by 13.27 percent. This is a 35.37 percent decrease over losses of $(0.82) per share
05-05 18:19
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted...
05-01 18:00
IDEAYA Biosciences Reveals Late-Breaking Abstract Oral Presentation At ASCO 2026 To Provide Complete Data from Phase 2/3 Registrational Trial Of Darovasertib In Combination With Crizotinib In 1L HLA*A2-Negative Metastatic Uveal Melanoma
- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced they have been selected for a late-breaking abstract (LBA) oral presentation to provide the complete data from the
04-21 22:18
美股大行评级 | 小摩上调Bloom Energy目标价从166美元升至231美元；目标价28美元！大摩、高盛等多家机构首予Janus Living(JAN)超配评级
今日重点评级关注：Ascendiant Capital：维持Banzai International"买入"评级，目标价从23美元升至24美元；Ascendiant Capital：维持Synergy CHC Corp."买入"评级，目标价从5美元升至5.5美元
04-15 11:31
